| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Ascrinvacumab | PF-3446962; GT-90001; PF-3-446-962; GT-90001C; ALK-1; GT90001C; PF-03446962 | Phase 2 Clinical | Pfizer Inc | Carcinoma, Hepatocellular; Colorectal Neoplasms; Liver Neoplasms; Macular Degeneration; Mesothelioma; Neoplasms; Solid tumours | Details |